Use of a Prenylation Inhibitor as a Novel Antiviral Agent

AUTOR(ES)

Glenn, Jeffrey S.

FONTE

American Society for Microbiology

RESUMO

No specific therapy exists for hepatitis delta virus (HDV), which can cause severe liver disease. Molecular genetic studies have implicated the prenylation site of large delta antigen as a critical determinant of HDV particle assembly. We have established a cell culture model which produces HDV-like particles, and we show that delta antigen prenylation can be pharmacologically inhibited by the prenylation inhibitor BZA-5B. Furthermore, BZA-5B specifically abolishes particle production in a dose-dependent manner. These results demonstrate that the use of such a prenylation inhibitor-based antiviral therapy may be feasible and identify a novel class of potential antiviral agents.

Documentos Relacionados

• Use of 2'-fluoro-5-methyl-beta-L-arabinofuranosyluracil as a novel antiviral agent for hepatitis B virus and Epstein-Barr virus.
• A novel antiviral agent which inhibits the endonuclease of influenza viruses.
• Novel Use of a Guanosine Prodrug Approach To Convert 2′,3′-Didehydro-2′,3′-Dideoxyguanosine into a Viable Antiviral Agent
• Preliminary Studies of the Mode of Action of Arildone, a Novel Antiviral Agent
• Reovirus as a novel oncolytic agent